Advertisement

European Journal of Clinical Pharmacology

, Volume 30, Issue 4, pp 445–451 | Cite as

Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy

  • W. L. Hayton
  • R. Schandlik
  • K. Stoeckel
Originals

Summary

Three groups of patients with biliary tract disease treated by cholecystectomy were given ceftriaxone. In Group 1 single doses of 150 mg and 1500 mg were given on Days 1 and 5 after cholecystectomy. In Group 2 2 g was given daily for 6 days and the cholecystectomy was on Day 2. Patients in Group 3 received 2 g every 12 h for 3 to 5 doses before cholecystectomy. Plasma samples, urine and T-drain bile were collected at various times from Groups 1 and 2 patients. Gallbladder bile and plasma were collected from Group 3 patients at the time of cholecystectomy. The mean (±SEM) T-drain bile-to-plasma concentration ratio of ceftriaxone in Groups 1 and 2 was 6.7±0.92. The mean (±SEM) gallbladder bile-to-plasma concentration ratio was 33±4.2. No clinically significant differences were detected between the kinetics of ceftriaxone in the cholecystectomy patients compared to normal volunteers. The usual dosage of ceftriaxone appeared adequate for prophylaxis or treatment of biliary tract infection by susceptible organisms.

Key words

ceftriaxone cholecystectomy cephalosporins biliary excretion T-drain bile pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arvidsson A, Alván G, Angelin B, Borgå O, Nord CE (1982) Ceftriaxone: Renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother 10: 207–215Google Scholar
  2. 2.
    Baumgartner JD, Glauser MP (1983) Pharmacokinetic and microbial susceptibility studies of ceftriaxone. Eur J Clin Microbiol 2: 501–504Google Scholar
  3. 3.
    Brogard JM, Arnaud JP, Timmler R (1984) Biliary excretion of ceftizoxime in humans. Chemotherapy 30: 221–226Google Scholar
  4. 4.
    Farquet C, Marti MC, Balant L, Cochet B, Rudhardt M, Fabre J, Rohner A (1982) Etude pharmacocinétique d'une céphalosporine: La céfopérazone chez des patients porteurs d'un drain de Kehr. Schweiz Med Wochenschr 112: 123–129Google Scholar
  5. 5.
    Gibaldi M, Perrier D (1982) Pharmacokinetics, Marcel Dekker New York, p 143Google Scholar
  6. 6.
    Hayton WL, Stoeckel K (1986) Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet 11: 76–86Google Scholar
  7. 7.
    Kemmerich B, Lode H, Borner K, Belmega D, Jendroschek T, Koeppe P, Goertz G (1983) Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother 19: 27–37Google Scholar
  8. 8.
    Maudgal DP, Maxwell JD, Lees LJ, Wild RN (1982) Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man. Br J Clin Pharmacol 14: 213–217Google Scholar
  9. 9.
    McNamara PJ, Gibaldi M, Stoeckel K (1983) Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding I. Theoretical considerations. Eur J Clin Pharmacol 25: 399–405Google Scholar
  10. 10.
    McNamara PJ, Gibaldi M, Stoeckel K (1983) Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding II. Physiological significance. Eur J Clin Pharmacol 25: 407–412Google Scholar
  11. 11.
    McNamara PJ, Stoeckel K, Ziegler WH (1982) Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur J Clin Pharmacol 22: 71–75Google Scholar
  12. 12.
    Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562–563Google Scholar
  13. 13.
    Ratzan KR, Baker HB, Lauredo I (1978) Excretion of cefamandole, cefazolin, and cephalothin into T-tube bile. Antimicrob Agents Chemother 13: 985–987Google Scholar
  14. 14.
    Ray AA (ed) (1982) SAS user's guide: Statistics. Cary, North Carolina, SAS InstituteGoogle Scholar
  15. 15.
    Reichen J, Paumgartner G (1980) Excretory function of the liver. In: Javitt NB (ed) Liver and biliary tract physiology. Int Rev Physiol 21: 103–150Google Scholar
  16. 16.
    Richards DM, Heel RC, Brogden TM, Speight TM, Avery GS (1984) Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 27: 469–527Google Scholar
  17. 17.
    Rollins DE (1984) Pharmacokinetics and drug excretion in bile. In: Benet LZ, Massoud N, Gambertoglio JG (eds) Pharmacokinetic basis for drug treatment. Raven Press, New York pp 77–88Google Scholar
  18. 18.
    Strange RC (1984) Hepatic bile flow. Physiol Rev 64: 1055–1102Google Scholar
  19. 19.
    Stoeckel K (1983) Pharmacokinetics of ceftriaxone, a long-acting broad-spectrum cephalosporin. In: Progress in therapy of bacterial infections. A new cephalosporin: Ceftriaxone. Excerpta Medica, Princeton pp 5–20Google Scholar
  20. 20.
    Stoeckel K, Koup JR (1984) Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic non-linear protein binding model. Am J Med 77 (4C): 26–32Google Scholar
  21. 21.
    Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH (1981) Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 29: 650–657Google Scholar
  22. 22.
    Stoeckel K, Tuerk H, Trueb V, McNamara PJ (1984) Single-dose ceftriaxone kinetics in liver insufficiency. Clin Pharmacol Ther 36: 500–509Google Scholar
  23. 23.
    Trautmann KH, Haefelfinger P (1981) Determination of Ro 13-9904 in plasma, urine and bile by means of ion-pair reversed phase chromatography. J High Resol Chromatogr Commun 4: 54–59Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • W. L. Hayton
    • 1
  • R. Schandlik
    • 2
  • K. Stoeckel
    • 1
  1. 1.Pharmaceutical Research DepartmentF. Hoffmann-La Roche & Co. LtdBaselSwitzerland
  2. 2.Regional HospitalSteyerAustria

Personalised recommendations